Release of experimental retinal vein occlusions by direct intraluminal injection of ocriplasmin

British Journal of Ophthalmology

Volumn 100, Issue 12, 2016, Pages 1742-1746

  De Smet, Marc D ^a,b   Stassen, Jean Marie ^c   Meenink, Thijs C M ^b   Janssens, Tom ^d   Vanheukelom, Valérie ^d   Naus, Gerrit J L ^b   Beelen, Maarten J ^b   Jonckx, Bart ^d  

^a MicroInvasive Ocular Surgery Center   (Switzerland)

^b Preceyes Bv   (Netherlands)

^c Crystapharm Bvba   (Belgium)

^d ThromboGenics NV   (Belgium)

Author keywords

Drugs; Experimental 8211 animal models; Pharmacology; Retina; Treatment Surgery

Indexed keywords

OCRIPLASMIN; ROSE BENGAL; PEPTIDE FRAGMENT; PLASMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANNULATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; ENDOLASER; FEASIBILITY STUDY; INTRALUMINAL DRUG ADMINISTRATION; MICROMANIPULATOR; NONHUMAN; OPTIC NERVE; PIG; PORCINE MODEL; PRIORITY JOURNAL; RETINA VEIN OCCLUSION; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; PROCEDURES; RETINA VEIN; ROBOTICS;

ANIMALS; DISEASE MODELS, ANIMAL; FIBRINOLYSIN; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; INJECTIONS, INTRAVENOUS; PEPTIDE FRAGMENTS; RETINAL VEIN; RETINAL VEIN OCCLUSION; ROBOTICS; SWINE;

EID: 84991486011     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2016-309190     Document Type: Article

References (25)

1. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmol 2010;117:313-19.
2. Green WR, Chan CC, Hutchins GM, et al. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 1981;79:371-422.
3. Bowers DK, Finkelstein D, Wolff SM, et al. Branch retinal vein occlusion. A clinicopathologic case report. Retina 1987;7:252-9.
4. Frangieh GT, Green WR, Barraquer-Somers E, et al. Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol 1982;100:1132-40.
5. Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haem 2010;8:1886-94.
6. Koferl P, Hollborn M, Rehak J, et al. Effects of arteriolar constriction on retinal gene expression and Muller cell responses in a rat model of branch retinal vein occlusion. Graefe's Arch Clin Exp Ophthalmol 2014;252:257-65.
7. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008;33:111-31.
8. Ameri H, Ratanapakorn T, Rao NA, et al. Natural course of experimental retinal vein occlusion in rabbit; arterial occlusion following venous photothrombosis. Graefe's Arch Clin Exp Ophthalmol 2008;246:1429-39.
9. Zhang Y, Fortune B, Atchaneeyasakul LO, et al. Natural history and histology in a rat model of laser-induced photothrombotic retinal vein occlusion. Curr Eye Res 2008;33:365-76.
10. de Smet MD, Meenink TCM, Janssens T, et al. Robotic Assisted Cannulation of Occluded Retinal Veins. PLoS ONE 2016;11:e0162037.
11. Okafor ON, Gorog DA. Endogenous fibrinolysis: an important mediator of thrombus formation and cardiovascular risk. J Am Coll Cardiol 2015;65:1683-99.
12. Pallis AG, Hatse S, Brouwers B, et al. Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging? J Geriat Oncol 2014;5:204-18.
13. Schaller J, Gerber SS. The plasmin-antiplasmin system: structural and functional aspects. Cellular and molecular life sciences. Cell Mol Life Sci 2011;68:785-801.
14. Raum D, Marcus D, Alper CA, et al. Synthesis of human plasminogen by the liver. Science 1980;208:1036-7.
15. Yamamoto T, Kamei M, Sakaguchi H, et al. Comparison of surgical treatments for central retinal vein occlusion; RON vs. cannulation of tissue plasminogen activator into the retinal vein. Retina 2009;29:1167-74.
16. Garcia-Arumi J, Martinez-Castillo V, Boixadera A, et al. Management of macular edema in branch retinal vein occlusion with sheathotomy and recombinant tissue plasminogen activator. Retina (Philadelphia, Pa) 2004;24:530-40.
17. Gad ElKareem A, Willikens B, Vanhove M, et al. Characterization of a stabilized form of microplasmin for the induction of a posterior vitreous detachment. Curr Eye Res 2010;35:909-15.
18. de Smet MD, Valmaggia C, Zarrantz J, et al. Microplasmin: ex vivo characterization of its activity in porcine vitreous. Invest Ophthalmol Vis Sci 2009;50:814-19.
19. Suzuki Y, Nagai N, Collen D. Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice. J Thromb Haem 2004;2:1617-21.
20. Nagai N, Demarsin E, van Hoef B, et al. Recombinant human microplasmin: production and potential therapeutic properties. J Thromb Haem 2003;1:307-13.
21. Bynoe LA, Hutchins RK, Lazarus HS, et al. Retinal endovascular surgery for central retinal vein occlusion. Initial experience of four surgeons. Retina 2005;25:625-32.
22. Feltgen N, Junker B, Agostini H, et al. Retinal endovascular lysis in ischemic central retinal vein occlusion: one-year results of a pilot study. Ophthalmol 2007;114:716-23.
23. Berker N, Batman C. Surgical treatment of central retinal vein occlusion. Acta Ophthalmol 2008;86:245-52.
24. Charbonnel J, Glacet-Bernard A, Korobelnik JF, et al. Management of branch retinal vein occlusion with vitrectomy and arteriovenous adventitial sheathotomy, the possible role of surgical posterior vitreous detachment. Graefe's Arch Clin Exp Ophthalmol 2004;242:223-8.
25. Lijnen H, Collen D. Mechanisms of physiological fibrinolysis. Baillière's Cin Haematol 1995;8:277-90.